Ligand binding is the fundamental event through which molecules interact in biological systems. Understanding the kinetics and equilibrium of binding is essential for characterizing receptors, enzymes, transporters, and drug-target interactions.
Binding Equilibrium
The simplest binding equilibrium is described by the reversible interaction between a ligand (L) and a receptor or target (R): R + L ⇌ RL. The association rate constant (ka or kon) and dissociation rate constant (kd or koff) define the dynamics. At equilibrium, the rate of association equals the rate of dissociation.
The equilibrium dissociation constant (KD) is defined as kd/ka and equals the ligand concentration at which half of the receptors are occupied. A lower KD indicates higher affinity. KD values range from picomolar for high-affinity interactions to millimolar for weak binding.
The binding isotherm describes the fraction of occupied receptors as a function of ligand concentration. For a simple bimolecular interaction, the relationship follows a rectangular hyperbola described by the Langmuir isotherm: fractional occupancy = [L] / ([L] + KD). This relationship is fundamental to understanding dose-response curves in pharmacology.
Association Kinetics
The association of a ligand with its target depends on diffusion and the formation of a productive encounter complex. The diffusion-limited association rate for small molecules with protein targets is approximately 109 M−1s−1. Most drug-target associations are slower, with kon values of 105–10^8 M−1s−1, reflecting steric and electrostatic barriers.
The association rate is measured by mixing ligand and target and monitoring complex formation in real time. The observed rate depends on both the association rate constant and the concentrations of the reactants. Under pseudo-first-order conditions where ligand is in excess, the observed rate is kon × [L] + koff.
Dissociation Kinetics
The dissociation rate constant (koff) determines how long the ligand remains bound to its target. The residence time, defined as 1/koff, is increasingly recognized as a critical parameter for drug efficacy. Long residence times can provide sustained target occupancy even after the free ligand concentration drops.
Dissociation kinetics are measured by diluting the pre-formed complex, adding a competitor to prevent reassociation, or using label-free methods. Slow dissociation (koff below 10^−4 s−1) corresponds to residence times of hours or longer.
Experimental Methods
Surface plasmon resonance (SPR) is the predominant label-free method for measuring binding kinetics. The target is immobilized on a sensor chip, and ligand solutions are flowed over the surface. Changes in refractive index report real-time binding and dissociation. Multi-cycle and single-cycle kinetics formats are available.
Bio-layer interferometry (BLI) measures binding through interference patterns of reflected light from a biosensor tip. It is similar to SPR but uses dip-and-read format with disposable tips.
Isothermal titration calorimetry (ITC) directly measures the heat released or absorbed during binding, providing KD, stoichiometry (n), enthalpy (ΔH), and entropy (ΔS) from a single experiment. ITC is solution-based and does not require immobilization.
Fluorescence-based methods including fluorescence polarization, FRET, and stopped-flow fluorescence offer high sensitivity and time resolution for measuring rapid kinetics. Radioactive ligand binding assays using filtration or scintillation proximity remain useful for high-throughput screening.
Cooperativity and Allostery
Many receptors and enzymes contain multiple binding sites. Positive cooperativity occurs when binding of one ligand increases the affinity of remaining sites, producing a sigmoidal binding curve. The Hill coefficient quantifies the degree of cooperativity. Negative cooperativity reduces affinity at remaining sites.
Allosteric modulators bind at sites distinct from the orthosteric binding pocket and alter the affinity or efficacy of the orthosteric ligand. Allosteric modulation can be positive (PAM), negative (NAM), or silent (neutral). Allosteric ligands offer potential advantages in drug discovery, including saturable effects and retained activity in the presence of high endogenous ligand concentrations.
Competitive and Non-Competitive Binding
Competitive inhibitors bind to the same site as the natural ligand and can be overcome by increasing ligand concentration. The IC50 shifts with substrate concentration in competitive inhibition. Non-competitive inhibitors bind to a different site and reduce the maximal response without affecting KD. Uncompetitive inhibitors bind only to the ligand-receptor complex.
Practical Considerations
Accurate determination of binding parameters requires careful experimental design. Nonspecific binding must be measured and subtracted. Ligand depletion can distort measurements if the ligand concentration is not in excess over the target. Aggregation and precipitation of compounds produce artifacts.
Data analysis uses nonlinear regression to fit binding curves to appropriate models. The Akaike information criterion (AIC) helps select between competing models. Residual analysis identifies systematic deviations from the fitted model.
